Prophylactic administration of ivermectin attenuates SARS-CoV-2 induced disease in a Syrian Hamster Model
Takayuki Uematsu, Tomomi Takano, Hidehito Matsui, Noritada Kobayashi, Satoshi Ōmura, Hideaki Hanaki
The Journal of Antibiotics, doi:10.1038/s41429-023-00623-0
, caused by SARS-CoV-2 infection, is currently among the most important public health concerns worldwide. Although several effective vaccines have been developed, there is an urgent clinical need for effective pharmaceutical treatments for treatment of COVID-19. Ivermectin, a chemical derivative of avermectin produced by Streptomyces avermitilis, is a macrocyclic lactone with antiparasitic activity. Recent studies have shown that ivermectin inhibits SARS-CoV-2 replication in vitro. In the present study, we investigated the in vivo effects of ivermectin in a hamster model of SARS-CoV-2 infection. The results of the present study demonstrate oral administration of ivermectin prior to SARS-CoV-2 infection in hamsters was associated with decreased weight loss and pulmonary inflammation. In addition, the administration of ivermectin reduced pulmonary viral titers and mRNA expression level of pro-inflammatory cytokines associated with severe COVID-19 disease. The administration of ivermectin rapidly induced the production of virus-specific neutralizing antibodies in the late stage of viral infection. Zinc concentrations leading to immune quiescence were also significantly higher in the lungs of ivermectin-treated hamsters compared to controls. These results indicate that ivermectin may have efficacy in reducing the development and severity of COVID-19 by affecting host immunity in a hamster model of SARS-CoV-2 infection.
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41429-023-00623-0. Infectious Diseases from the Japan Agency for Medical Research and Development, under grant JP20fk0108158 to HH.
Compliance with ethical standards Conflict of interest The authors declare no competing interests. Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.
References
Arévalo, Ivermectin reduces in vivo coronavirus infection in a mouse experimental model, Sci Rep
Blondeau, Immunomodulatory Effects of Macrolides Considering Evidence from Human and Veterinary Medicine, Microorganisms
Brevini, FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2, Nature
Caly, Druce, Catton, Jans, Wagstaff, The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir Res
Chan, Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility, Clin Infect Dis
Collier, Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies, Nature
Crump, Omura, Ivermectin, 'Wonder drug' from Japan: The human use perspective, Proc Jpn Acad Sers B Phys Biol Sci
De Melo, Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin, EMBO Mol Med
Ebisudani, Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening, Cell Rep
Flerlage, Boyd, Meliopoulos, Thomas, Schultz-Cherry, Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract, Nat Rev Microbiol
Hirano, Roles of Zinc and Zinc Signaling in Immunity: Zinc as an Intracellular Signaling Molecule, Adv Immunol
Imai, Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development, Proc Nat Acad Sci
Israel, Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study, BMJ
Jin, The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism, Nat Commun
Kaur, Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes, Pharm Rep
Khezri, Zolbanin, Ghasemnejad-Berenji, Jafari, Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection, Eur J Pharm
Kitamura, Toll-like receptor-mediated regulation of zinc homeostasis influences dendritic cell function, Nat Immunol
Kumar, Kubota, Chernov, Kasuya, Potential role of zinc supplementation in prophylaxis and treatment of COVID-19, Med Hypotheses
Ladds, Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients and draft quality principles for services, BMC Health Serv Res
Matsuyama, Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells, Proc Nat Acad Sci
Nambara, Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer, Oncotarget
Namkoong, Clarithromycin expands CD11b+Gr-1+ cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and postinfluenza bacterial pneumonia, PLoS Pathog
Nishio, Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice, Proc Natl Acad Sci
Popp, Ivermectin for preventing and treating COVID-19, Cochrane Database Syst Rev
Puntmann, Vo, Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered from Coronavirus Disease 2019 (COVID-19), JAMA Cardiol
Ramos-Casals, Brito-Zerón, Systemic and organspecific immune-related manifestations of COVID-19, Nat Rev Rheumatol
Rawat, Kumari, Saha, COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies, Eur J Pharm
Schultze, Aschenbrenner, COVID-19 and the human innate immune system, Cell
Sharma, Sultan, Ding, Triggle, A Review of the Progress and Challenges of Developing a Vaccine for COVID-19, Front Immunol
Sia, Pathogenesis and transmission of SARS-CoV-2 in golden hamsters, Nature
Stratton, Tang, Lu, Pathogenesis-directed therapy of 2019 novel coronavirus disease, J Med Virol
Velthuis, Zn2+ Inhibits Coronavirus and RNA Polymerase Activity In and Zinc Ionophores Block the Replication of These Viruses in Cell Culture, PLoS Pathog
Venditto, Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19, Front Immunol
Vig, Kinet, Calcium signaling in immune cells, Nat Immunol
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J
Wang, SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease, Emerg Microbes Infect
Wiersinga, Rhodes, Cheng, Peacock, Prescott, Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review, JAMA
Xu, Antivirus effectiveness of ivermectin on dengue virus type 2 in Aedes albopictus, PLoS Negl Trop Dis
Yang, The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antivir Res
Õmura, Crump, The life and times of ivermectin-A success story, Nat Rev Microbiol
